MiniMed Group (MMED) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- $0.10
- Surprise
- -100.0%
- Score today
- 5.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21 — benzinga, 2026-09-03
- Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26 — benzinga, 2026-09-02
- Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27 — benzinga, 2026-09-02
Where TrendMatrix's rating stands now
TrendMatrix currently rates MMED Sell at 5.9/10; no pre/post engine snapshot brackets this report.
0 of the last 3 quarters beat the estimate; this quarter's -100.0% surprise compares with a -111.9% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Concentration risk — Supplier: Convatec, Forj Medical and Steris sole-source suppliers
- Target reached (-10.9% upside)
- Quality below floor (3.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.30
- Price target
- $27.42
- Stop
- $22.17
- Upside to target
- +17.7%
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 2.3× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
MMED at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $6.68B
- P/E (fwd)
- 36.6
- 52-week range
- $10.65–$24.43
- Off 52-week high
- 4.6%
- RSI (14)
- 72
- Volume vs avg
- 2.29×
- Score today
- 5.9/10